Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), respectively, at the 59th European Renal Association (ERA) Congress. The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. ERA is being held live in Paris, France, and virtually May 19-22, 2022.

Read the full press release >

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Read the full press release >

Stephanie

,
In the spring of 2020, after a hike with her husband and kids, Stephanie’s legs swelled unfathomably. She took a video of herself pressing her fingers into her legs, showing how her fingers would sink into the skin.

Travere Therapeutics Reports First Quarter 2022 Financial Results

SAN DIEGO, May 5, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.

Read the full press release >

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

SAN DIEGO , April 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief financial officer Laura Clague, CPA, will retire after serving in this role for the past seven years. Ms. Clague will step down from the CFO position in August 2022 and will remain employed by the Company in an advisory capacity into 2023 to facilitate a smooth transition. Chris Cline, CFA, the Company’s current senior vice president of investor relations and corporate communications and a member of the senior leadership team, has been named Ms. Clague’s successor as chief financial officer, to be effective in August 2022.

Read the full press release >
Rare Life: George

George

,
George and his family love history. They enjoy road trips to Williamsburg, Amish country, Civil War and Revolutionary War sites, and any other spot of historical interest. Along with George, their four kids benefit from their mom’s passion as a U.S. history teacher, making stories of the past relevant to life today. George’s personal history includes an ultra-rare disorder diagnosis of cerebrotendinous xanthomatosis, or CTX. But like so many rare disorder diagnosis stories, his began as a mystery.

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022

SAN DIEGO , April 06, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU).

Read the full press release >

Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Read the full press release >
Sharron and Shonte'

Sharron & Shonté

,
"If you need something and I have it, it’s yours.” These are the words of Sharron’s sister Shonté when Sharron’s rare kidney disease, FSGS, progressed to end-stage kidney disease. Watch the story of two sisters who each gave something to the other, helping both live fully.
Fierce Healthcare logo

Coalition of healthcare organizations, experts push forward to improve equity in rare diseases

March 3, 2022 -- Fierce Healthcare featured Eve Dryer, vice president of patient advocacy at Travere Therapeutics, and partners Global Genes and Rare Disease Diversity Coalition in an article about disparities in rare disease care.